Chief Growth Officer Adds $1.18M More — Now Holds 4.17M Shares
HELP has more than doubled off its 52-week low of $3.76.
Summary
Cybin's Chief Growth Officer bought $1.18M more stock at $11.78, adding to a $1.04M purchase disclosed yesterday. Total recent insider buying now exceeds $2.2M.
Key Events · Ownership and Investor Activity · HELP
-
CGO Buys $1.18M More Stock
Paul Glavine purchased 100,000 shares at $11.78 per share on September 3, 2026, spending $1,178,280 in a single open-market transaction.
-
Two-Day Insider Buying Tops $2.2M
Combined with the $1.04M purchase at $11.59 disclosed on September 9, Glavine has now bought over $2.2M of Cybin stock in the past week.
-
Direct Holdings Reach 4.17M Shares
Post-transaction direct ownership is 4,171,252 shares, plus 230,941 shares held indirectly through the PLG Family Trust.
-
Buying Near 52-Week High
The purchase at $11.78 occurred with the stock trading near its 52-week high of $14.35, signaling strong conviction despite the elevated price.
Analysis · HELP · Life Sciences
Paul Glavine, Cybin's Chief Growth Officer, bought another 100,000 shares on the open market at $11.78 per share on September 3, spending $1,178,280. This comes one day after a separate $1.04M purchase at $11.59 was disclosed, bringing his total recent open-market buying to over $2.2M. The stock is trading near its 52-week high of $14.35, and Glavine is buying with real cash — not exercising options. For a company with a market cap of only $1.39M, this level of insider accumulation is extraordinary and suggests management sees significant upside ahead of the Phase 3 HLP003 data readout.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.9% of the 578 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HELP was trading at $13.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $3.76 to $14.35. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.